Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene

By Ko Seung Sang   Jordan V Craig  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 4, 2011-03 ,pp. : 657-674

Informa Healthcare

Access to resources Recommend Favorite

The STAR Trial: Evidence for Raloxifene as a Breast Cancer Risk Reduction Agent for Postmenopausal Women

By Bevers Therese B.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 5, Iss. 8, 2007-09 ,pp. : 817-822

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Benefit-Risk Assessment of Raloxifene in Postmenopausal Osteoporosis

By Cranney Ann  

Drug Safety, Vol. 28, Iss. 8, 2005-01 ,pp. : 721-730

Adis International

Access to resources Recommend Favorite

Fulvestrant – a new treatment for postmenopausal women with hormone-sensitive advanced breast cancer

By Possinger Kurt  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 12, 2004-12 ,pp. : 2549-2558

Informa Healthcare

Access to resources Recommend Favorite

Cost Effectiveness of Letrozole in the Treatment of Advanced Breast Cancer in Postmenopausal Women in the UK

By Nuijten M.  

PharmacoEconomics, Vol. 16, Iss. 4, 1999-10 ,pp. : 379-397

Adis International

Access to resources Recommend Favorite